XPANSIV
23.3.2022 14:23:04 CET | Business Wire | Press release
Xpansiv, the global marketplace for ESG commodities, today announced the launch of Digital Crude Oil™ (DCO), the latest addition to the Xpansiv Digital Fuels™ Program . DCO units registered on the Xpansiv DF Registry enable markets to differentiate crude oil based on greenhouse-gas emissions and ESG performance.
The inaugural DCOs will be registered from Lundin Energy ’s North Sea production, representing carbon intensity and other key environmental attributes for individual barrels of oil.
“This is a critical moment of confluence between two paradigm shifts in global energy, digitization and decarbonization,” said Xpansiv CEO Joe Madden. “The energy transition will be driven by greater data transparency, so crude oil producers like Lundin Energy with improved ESG performance are rewarded with a clear price signal. The Xpansiv platform provides the financial infrastructure—from source data to market outcomes—that enables this shift in the valuation of global commodities.”
“The time has come for a differentiated market for responsibly produced oil and gas,” said Lundin Energy CFO Teitur Poulsen. “We have already sold certified, carbon-neutrally produced crude cargoes, which indicates the demand signals are real. Certification and traceability are key to creating a credible market for responsibly produced hydrocarbons, and we’re pleased to work with Xpansiv to help develop this market in the right way.”
Certification-company Intertek has also joined the Xpansiv Digital Fuels Program ecosystem as DCO-certification partner, adding another source of data-quality assurance, carbon-intensity benchmarking, and independent certifications.
Xpansiv created the Digital Fuels Program to support the creation, issuance, registration, management, trading, and retirement of encrypted digital twins that include the environmental attributes of fuels. The program includes a burgeoning network of energy producers, data refineries, monitoring networks, lifecycle assessments, standards and certification organizations, and downstream market participants—all operating under a Governance Framework that specifies data quality and management protocols, as well as full lifecycle requirements for these new digital assets.
Similar to DNGs, DCOs bring transparency and precision to measuring the ESG impacts of crude-oil production based on immutable data, auditable from source to market. “Trust from all stakeholders in the sustainability journey will only happen with total transparency, and Intertek is proud to be a part of the energy industry’s journey,” said Intertek SVP Total Energy Malissa Boudreaux.
In September, Xpansiv announced the first transaction of Digital Natural Gas ® (DNG™ ) through its DF Registry. Since then, more than 2,000 Methane Performance Certificates (MPCs) have traded, with daily price assessments provided by S&P Global Platts. DNG empowers downstream customers to demonstrate quantified progress in meeting methane-reduction commitments and net-zero goals based on empirical data. Producers are uploading approximately 1 billion cubic feet of natural gas data onto the Xpansiv platform every day to create DNG.
“Digital Crude Oil again demonstrates how the Xpansiv platform can ingest and contextualize complex data from multiple sources according to rigorous governance rules,” said Xpansiv Sustainability Director Jeff Cohen. “As a result, we can now differentiate raw-material inputs to global supply chains based on environmental performance innovations—information that was previously invisible to markets.”
About Xpansiv
Xpansiv is the global marketplace for ESG-inclusive commodities. These Intelligent Commodities bring transparency and liquidity to markets, empowering participants to value energy, carbon, and water to meet the challenges of an information-rich, resource-constrained world. The company’s main business units include CBL , the largest spot exchange for ESG commodities, including carbon, renewable energy certificates, and Digital Natural Gas; H2OX , the leading spot exchange for water; XSignals , which provides end-of-day and historical market data; and EMA , the leading multi-registry portfolio management system for all ESG-inclusive commodities. Xpansiv is the digital nexus where ESG and price signals merge. Xpansiv.com
About Lundin Energy
Lundin Energy is an experienced Nordic oil and gas company that explores for, develops, and produces resources economically, efficiently, and responsibly. We focus on value creation for our shareholders and wider stakeholders through three strategic pillars: Resilience, Sustainability, and Growth. Our high-quality, low-cost assets mean we are resilient to oil-price volatility, and our organic growth strategy, combined with our sustainable approach and commitment to decarbonisation, firmly establishes our leadership role in a lower carbon energy future. lundin-energy.com
About Intertek
Intertek is a leading Total Quality Assurance provider to industries worldwide. Our network of more than 1,000 laboratories and offices in more than 100 countries delivers innovative and bespoke Assurance, Testing, Inspection, and Certification solutions for our customers' operations and supply chains. Intertek Total Quality Assurance expertise—delivered consistently with precision, pace, and passion—enables our customers to power ahead safely. intertek.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20220323005506/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release
- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release
New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release
Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release
Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom